Name: CJC-1295 without DAC 5mg + IPA 5mg
Alias: Mod GRF 1-29 & Ipamorelin Blend
CAS Registry number: Mixed peptides (863288-34-0 & 170895-03-9)
Sequence:
CJC-1295 without DAC: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH?
Ipamorelin: H-Aib-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH?
Molecular Formula: Mixed formula (C???H???N??O??S + C??H??N??O?)
Molecular Weight: Mixed (3367.98 Da + 711.02 Da)
Purity: ≥99% (by HPLC for each single peptide component)
Appearance: White lyophilized powder
Packing: 10 vials/box (10mg total per vial, 5mg CJC-1295 without DAC + 5mg Ipamorelin)
Product Group: Mixed growth hormone regulatory peptide blend
Storage Conditions: Store at -20℃ in a dry, dark place; avoid repeated freeze-thaw cycles.
Brief Introduction:
CJC-1295 without DAC 5mg + IPA 5mg is a compound growth hormone regulatory peptide mixture exclusively for laboratory research. It combines two classic GH-regulating peptides with complementary synergistic effects. CJC-1295 without DAC acts on pituitary GHRH receptors to sustain steady growth hormone release, while Ipamorelin selectively activates ghrelin receptors to boost GH secretion without obvious prolactin elevation. The compound formula achieves stable, long-lasting pulsatile GH elevation, balancing muscle anabolism and fat metabolism, widely applied in endocrinology, body composition and aging-related mechanism research.
Main Research Applications:
Growth hormone synergy endocrine research: Used in cell and animal models to study dual-peptide combined GH release, pulsatile hormone secretion and receptor cross-regulation mechanisms.
Muscle anabolism & lipolysis research: Suitable for exploring lean muscle mass accumulation and adipose fat breakdown regulatory pathways.
Mild hormone balance research: Applied to investigate low-prolactin GH elevation and endocrine steady state maintenance.
Anti-aging & body composition research: For comparative analysis of age-related hormone decline and metabolic remodeling intervention.
Peptide compound formulation research: Study dosage matching and synergistic metabolic effects of GHRH analog and selective GHSR agonist.
Note:
This product is for laboratory research use only. It is not intended for human or animal therapeutic use, clinical trials, or any form of in vivo administration without prior ethical approval and regulatory authorization.